Receptor-mediated airway smooth muscle (ASM) contraction via G αq , and relaxation via G αs , underlie the bronchospastic features of asthma and its treatment. Asthma models show increased ASM G αi expression, considered the basis for the proasthmatic phenotypes of enhanced bronchial hyperreactivity to contraction mediated by M 3 -muscarinic receptors and diminished relaxation mediated by β 2 -adrenergic receptors (β 2 ARs). A causal effect between G i expression and phenotype has not been established, nor have mechanisms whereby G i modulates G q /G s signaling. To delineate isolated effects of altered G i , transgenic mice were generated overexpressing G αi2 or a G αi2 peptide inhibitor in ASM. Unexpectedly, G αi2 overexpression decreased contractility to methacholine, while G αi2 inhibition enhanced contraction. These opposite phenotypes resulted from different crosstalk loci within the G q signaling network: decreased phospholipase C and increased PKCα, respectively. G αi2 overexpression decreased β 2 AR-mediated airway relaxation, while G αi2 inhibition increased this response, consistent with physiologically relevant coupling of this receptor to both G s and G i . IL-13 transgenic mice (a model of asthma), which developed increased ASM G αi , displayed marked increases in airway hyperresponsiveness when G αi function was inhibited. Increased G αi in asthma is therefore a double-edged sword: a compensatory event mitigating against bronchial hyperreactivity, but a mechanism that evokes β-agonist resistance. By selective intervention within these multipronged signaling modules, advantageous G s /G q activities could provide new asthma therapies.
IntroductionAirway smooth muscle (ASM) contraction and relaxation are primarily regulated by G protein-coupled receptors, the former mediated by receptors signaling to G q and the latter by those that couple to G s (1, 2). Many inflammatory cascades in asthma evoke bronchoconstriction by promoting local increases of G q receptor agonists such as acetylcholine, cysteinyl leukotrienes, prostaglandins, and histamine, which activate their cognate receptors expressed on ASM. There appear to be fewer G s -coupled receptors that act via endogenous agonists to counteract bronchoconstriction, but the β 2 -adrenergic receptor (β 2 AR) of ASM is the target of pharmacologically administered β-agonists and is typically highly effective in relaxing constricted airways. The molecular events and critical transduction elements for these 2 classes of receptors are well recognized. Agonist binding to receptors such as the M 3 -muscarinic receptor promote disassociation of heterotrimeric G q into G α and G βγ subunits, with the α subunit activating phospholipase C (PLC; which promotes inositol-3 phosphate and diacylglycerol production) and the latter activating PKC. Receptors such as the β 2 AR act via G αs to stimulate the effector adenylyl cyclase, resulting in cAMP production and activation of PKA. Substantial interest has